SynthesisFrontiers in oncology2022
Current status and challenges of immunotherapy in ALK rearranged NSCLC.
Rongbin Qi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it
SynthesisFrontiers in oncology2022
Rongbin Qi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.